反応式
[CH3:1][C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][C:3]=1[N:8]1[C:12](=[O:13])[CH2:11][S:10]/[C:9]/1=[N:14]\[CH:15]([CH3:17])[CH3:16].[O:18]1[C:23]2[CH:24]=[CH:25][C:26]([CH:28]=O)=[CH:27][C:22]=2[O:21][CH2:20][CH2:19]1.C([O-])(=O)C.[Na+]>C(O)(=O)C>[O:18]1[C:23]2[CH:24]=[CH:25][C:26](/[CH:28]=[C:11]3/[C:12](=[O:13])[N:8]([C:3]4[CH:4]=[CH:5][CH:6]=[CH:7][C:2]=4[CH3:1])/[C:9](=[N:14]/[CH:15]([CH3:17])[CH3:16])/[S:10]/3)=[CH:27][C:22]=2[O:21][CH2:20][CH2:19]1参加物
5
実験手順
A solution of 3-(2-methylphenyl)-2-[(Z)-isopropylimino]-thiazolidin-4-one (50 mg, 0.200 mmol), 2,3-dihydro-benzo[1,4]dioxine-6-carbaldehyde (49 mg, 0.300 mmol) and sodium acetate (33 mg, 0.400 mmol) in acetic acid (1 mL) is stirred at 110° C. for 5 h. The reaction mixture is cooled to rt and subjected to prep. HPLC purification. The product containing fractions are evaporated and dried to give 5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmeth-(Z)-ylidene)-2-[(Z)-isopropylimino]-3-o-tolyl-thiazolidin-4-one.
後処理
- customHPLC purification
- additionThe product containing fractions
- customare evaporated
- customdried
出典と根拠
- ORDレコード
- ord-87e5fe62015a43dd8ee41f09b19d01e6
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08524752B2
関連ノート
読み込み中…